We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S. The Board of Directors' decision on a new execution...
Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S...
Consolidated Interim report 1 January – 30 September 2024 Consolidated Interim report 1 January – 30 September 2024 Company announcement no. 30 – November 15, 2024 Key points from the Q1-Q3-2024...
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051. Pharma Equity Group's...
Major shareholder announcement - Pharma Equity Group A/S Major shareholder announcement - Pharma Equity Group A/S 14 October 2024Announcement No. 28 Pharma Equity Group A/S has, in...
Managers’ transactions October 14,2024Announcement no. 27 Managers’ transactions Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014...
Pharma Equity Group announces successful completion of directed issue of new shares Pharma Equity Group announces successful completion of directed issue of new shares 11 October 2024Company...
Pharma Equity Group announces issuance of new shares in a direct issue Pharma Equity Group announces issuance of new shares in a direct issue Inside information4 October 2024Company...
Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights Registration of capital reduction by way of a...
Consolidated Interim Report 1 January – 30 June 2024 Consolidated Interim Report 1 January – 30 June 2024 Company announcement no. 23 – August 16, 2024 Key points from the H1-2024 report (period 1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
4 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
12 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
26 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
52 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
156 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
260 | 0 | 0 | 0.4 | 0.4 | 0.4 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions